BiotechTube

NX-5948

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Lymphocytic Leukemia (CLL)

Conditions

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)

Trial Timeline

Apr 13, 2022 → Jan 1, 2028

NCT ID
NCT05131022

About NX-5948

NX-5948 is a phase 1 stage product being developed by Nurix Therapeutics for Chronic Lymphocytic Leukemia (CLL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05131022. Target conditions include Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Lymphocytic Leukemia (CLL) were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07221500Phase 2Recruiting
NCT06691828Phase 1Completed
NCT05131022Phase 1Recruiting

Competing Products

20 competing products in Chronic Lymphocytic Leukemia (CLL)

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25